UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   October 12, 2007

AMDL, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

     
Delaware 0-27689 33-0413161
_____________________
(State or other jurisdiction
_____________
(Commission
______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
2492 Walnut Avenue, Suite 100, Tustin, California   92780
_________________________________
(Address of principal executive offices)
  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   714-505-4461

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 8.01 Other Events.

On October 12, 2007 the Company filed a new application with the U.S. FDA under Section 510(k) of the Food, Drug and Cosmetic Act along with new statistical data to obtain approval to market DR-70 in the United States as an aid in monitoring patients with colorectal cancer. The nature and timing of the FDA's response to the Company's submission of the application cannot be anticipated, nor can there be any assurance that the FDA will clear DR-70 for use in the United States.





Item 9.01 Financial Statements and Exhibits.

(c) Exhibits.
99.1 Press Release announcing the filing of the application with the FDA on October 12, 2007.






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    AMDL, Inc.
          
October 12, 2007   By:   /s/Gary L. Dreher
       
        Name: Gary L. Dreher
        Title: Chief Executive Officer


Exhibit Index


     
Exhibit No.   Description

 
99.1
  Press Release to be issued October 15, 2007
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Amdl Charts.
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Amdl Charts.